Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Sunshine Biopharma (SBFM) Cost of Revenue (2018 - 2025)

Sunshine Biopharma (SBFM) has disclosed Cost of Revenue for 8 consecutive years, with $6.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cost of Revenue rose 13.91% year-over-year to $6.3 million, compared with a TTM value of $42.0 million through Sep 2025, up 1395.34%, and an annual FY2024 reading of $24.2 million, up 3196.5% over the prior year.
  • Cost of Revenue was $6.3 million for Q3 2025 at Sunshine Biopharma, up from $6.0 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $23.5 million in Q4 2024 and bottomed at -$9.9 million in Q4 2023.
  • Average Cost of Revenue over 5 years is $2.7 million, with a median of $198046.0 recorded in 2024.
  • Peak annual rise in Cost of Revenue hit 4731.24% in 2023, while the deepest fall reached 504.59% in 2023.
  • Year by year, Cost of Revenue stood at $61289.0 in 2021, then soared by 3895.36% to $2.4 million in 2022, then tumbled by 504.59% to -$9.9 million in 2023, then surged by 336.87% to $23.5 million in 2024, then tumbled by 72.97% to $6.3 million in 2025.
  • Business Quant data shows Cost of Revenue for SBFM at $6.3 million in Q3 2025, $6.0 million in Q2 2025, and $6.2 million in Q1 2025.